1. Real‐life patterns of use, safety and effectiveness of sunitinib in first‐line therapy of metastatic renal cell carcinoma: the SANTORIN cohort study
   Pernelle Noize et al, 2017, Pharmacoepidemiology and Drug Safety CrossRef
2. Central and Eastern European Experience with Sunitinib in Metastatic Renal Cell Carcinoma: A Sub-analysis of the Global Expanded-Access Trial
   Eduard Vrdoljak et al, 2015, Pathology & Oncology Research CrossRef
3. Safety and treatment patterns of angiogenesis inhibitors in patients with advanced renal cell carcinoma in Spain
   Daniel Castellano et al, 2013, Expert Opinion on Drug Safety CrossRef
4. Role of dose exposure and inflammatory status in a single center, real-world analysis of sunitinib in patients with metastatic renal cell carcinoma
   Marco Maruzzo et al, 2016, Future Oncology CrossRef
5. Safety and activity of sunitinib in elderly patients (≥70 years) with metastatic renal cell carcinoma: a multicenter study
   A. Brunello et al, 2013, Annals of Oncology CrossRef
6. Clear cell carcinoma of the ovary: A report from the first Ovarian Clear Cell Symposium, June 24th, 2010
   Michael S. Anglesio et al, 2011, Gynecologic Oncology CrossRef
7. Anticancer Compounds Based on Isatin-Derivatives: Strategies to Ameliorate Selectivity and Efficiency
   Raphael Enoque Ferraz de Paiva et al, 2021, Frontiers in Molecular Biosciences CrossRef
8. Assessment of ethnic differences in sunitinib outcome between Caucasian and Asian patients with metastatic renal cell carcinoma: a meta-analysis
   Xiaoyan Liu et al, 2017, Acta Oncologica CrossRef
9. Sunitinib adverse events in metastatic renal cell carcinoma: a meta-analysis
   Ezzeldin M. Ibrahim et al, 2013, International Journal of Clinical Oncology CrossRef
10. Synergistic Survival: A New Phenomenon Connected to Adverse Events of First-Line Sunitinib Treatment in Advanced Renal Cell Carcinoma
    Krisztián Nagyiványi et al, 2016, Clinical Genitourinary Cancer CrossRef
11. Sunitinib treatment in patients with advanced renal cell cancer: the Brazilian National Cancer Institute (INCA) experience
    Rafael Corrêa Coelho et al, 2016, International braz j urol CrossRef
12. Sunitinib therapy for metastatic renal cell carcinoma: A urologist’s perspective
    M Darrad et al, 2016, Journal of Clinical Urology CrossRef
13. Solitary Clear Cell Renal Cell Carcinoma Metastasis to the Eyelid: A Case Report
    Ognjen Zrinšćak et al, 2024, Case Reports in Oncology CrossRef
14. Angiogenesis inhibitor therapies for advanced renal cell carcinoma: Toxicity and treatment patterns in clinical practice from a global medical chart review
    WILLIAM K. OH et al, 2014, International Journal of Oncology CrossRef
15. Impact of adverse events, treatment modifications, and dose intensity on survival among patients with advanced renal cell carcinoma treated with first‐line sunitinib: a medical chart review across ten centers in five European countries
    Camillo Porta et al, 2014, Cancer Medicine CrossRef